



VOLUME FIFTY EIGHT

PROGRESS IN MEDICINAL CHEMISTRY

Edited by

DAVID R. WITTY

*Director Witnet Ltd,
Platinum Building,
St John's Innovation Park,
Cowley Road, Cambridge CB4 0DS,
United Kingdom*

BRIAN COX

*Professor of Pharmaceutical Chemistry,
Chichester 3 3R341,
School of Life Sciences,
University of Sussex,
Brighton, BN1 9RH,
United Kingdom*



Contents

| | |
|--|------------|
| <i>Contributors</i> | <i>vii</i> |
| <i>Preface</i> | <i>ix</i> |
| 1. Covalent binders in drug discovery | 1 |
| Anil Vasudevan, Maria A. Argiriadi, Aleksandra Baranczak, Michael M. Friedman, Julia Gavriluk, Adrian D. Hobson, Jonathan J. Hulce, Sami Osman, and Noel S. Wilson | |
| 1. Introduction | 2 |
| 2. Types of covalent binders | 3 |
| 3. Structure-based considerations | 26 |
| 4. Approved/clinical covalent inhibitors | 33 |
| 5. Covalent probes in chemical biology | 40 |
| 6. Natural products as ADC payloads | 46 |
| 7. Summary | 52 |
| References | 53 |
| Further reading | 62 |
| 2. Amyotrophic lateral sclerosis | 63 |
| Klara Valko and Lukasz Ciesla | |
| 1. Amyotrophic lateral sclerosis (ALS) | 64 |
| 2. Potential cellular signalling pathways that could be targeted for the treatment of motoneuron diseases | 70 |
| 3. Current markers and animal models used to evaluate the effect of new therapeutics in ALS | 81 |
| 4. Current medicinal chemistry approaches | 84 |
| 5. Summary of current approaches and future directions | 105 |
| Acknowledgements | 108 |
| References | 108 |
| 3. Rewriting the (tran)script: Application to spinal muscular atrophy | 119 |
| Hasane Ratni, Lutz Mueller, and Martin Ebeling | |
| 1. Introduction | 119 |
| 2. Splicing modulation | 120 |
| 3. Spinal muscular atrophy (SMA) | 123 |
| 4. Discovery of nusinersen | 125 |

| | |
|---|------------|
| 5. Discovery of branaplam | 127 |
| 6. Discovery of risdiplam | 130 |
| 7. Selectivity of risdiplam compared to other small molecule splicing modifiers | 144 |
| 8. Impact of selectivity | 150 |
| 9. Conclusion | 151 |
| References | 152 |
| 4. Natural product drug delivery: A special challenge? | 157 |
| Neil J. Press, Emilie Joly, and Peter Ertl | |
| 1. Introduction | 158 |
| 2. Cyclosporine A | 160 |
| 3. Doxorubicin | 162 |
| 4. Insulin | 164 |
| 5. Rapamycin and analogues | 167 |
| 6. Penicillin | 171 |
| 7. Morphine | 175 |
| 8. Paclitaxel (Taxol [®]) | 177 |
| 9. Additional strategies | 180 |
| 10. Conclusions | 181 |
| References | 182 |